

2015 CORPORATE FACTSHEET

Updated on May 21st 2015

www.iba-worldwide.com




ABOUT IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

TURNOVER 2014

TOTAL EUR 221 MILLION



BUSINESS SEGMENTS

PROTON THERAPY

Around 50% of all cancer patients receive radiation as part of their treatment program.

However conventional beams also deliver damaging radiation to healthy tissues surrounding the tumor site. Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced patient side effects. This increased accuracy is especially important when treating cancers near to radio-sensitive tissues such as the head or neck and in pediatric cases.

To date, IBA has the world's largest installed base with more than 30 proton therapy centers worldwide. IBA is also leading the field in proton therapy innovation, making proton therapy more accessible and affordable through five room to single room systems.

The proven efficacy of IBA's proton therapy products which have been cleared by the FDA and other agencies has enabled more than 40 000 patients worldwide to benefit from IBA's proton therapy cancer treatment.

IBA IS THE WORLD LEADER IN CLINICAL PROTON THERAPY



RADIOPHARMACY SOLUTIONS

Based on 30 years of expertise (in 2016), IBA offers a global solution for radioisotopes production.

IBA's expertise is in equipment development, production, installation and the maintenance of integrated facilities for the production of radioisotopes and radiopharmaceutical tracers.

IBA supports hospitals and radiopharmaceutical centers, assisting with the design and installation across their facility, providing support to the process and a full range of training programs.

IBA IS THE WORLD LEADER IN INTEGRATED RADIOPHARMACIES



DOSIMETRY

Precision is everything in the delivery of radiation.

For both diagnosis and therapy, delivering exactly the prescribed dose to a precisely defined area in the patient's body is absolutely crucial. Treatment success and safety depend on it.

IBA offers a full range of monitoring equipment and software enabling radiologists to perform the necessary checks and calibration procedures.


IBA IS THE WORLD LEADER IN DOSIMETRY



IBA SA.

Chemin du Cyclotron, 3 – 1348 Louvain-la-Neuve, Belgium
Tel. : +32 10 47 58 11 – Fax : +32 10 47 58 11

E-mail : info-worldwide@iba-group.com – www.iba-worldwide.com
RPM Nivelles – TVA : BE 0428.750.985



MANAGEMENT TEAM

OLIVIER LEGRAIN

Chief Executive Officer

YVES JONGEN

Chief Research Officer

JEAN-MARC BOTHY

Chief Financial Officer

ROB PLOMPEN

President
IBA Dosimetry

FRÉDÉRIC NOLF

Chief Human
Resources Office

BOARD OF DIRECTORS

PIERRE MOTTET

Chairman of the IBA Board /
formerly Chief Executive Officer of IBA /
Member of the Executive Committee
of FEB (Federation of Enterprises in
Belgium), Director of UWE (Walloon
Business Association), Agoria and
several startups

YVES JONGEN

Founder / Chief Research Officer/
Managing Director of IBA

SYBILLE VAN DEN HOVE

Member of the IBA Board of Directors since
May 2015 / Director, Median SCP, Barcelona /
Visiting Professor, Institute of Environmental
Sciences and Technologies (ICTA),
Autonomous University of Barcelona / Chair,
Scientific Committee, European Environment
Agency

OLIVIER LEGRAIN

Chief Executive Officer and
Managing Director of IBA

DR. MARY GOSPODAROWICZ

Professor, Staff Radiation Oncologist,
Radiation Medicine Program, Princess
Margaret Cancer Centre, University
Health Network, Toronto /
Medical Director, Princess Margaret
Cancer Centre, University Health
Network, Toronto /
Regional Vice-President, Cancer
Care Ontario, Toronto /
President, Union for International
Cancer Control

ERIC DE LAMOTTE

Formerly Chief Financial Officer of IBA

KATLEEN VANDEWEYER

Chief Financial Officer Atos Worldwide

MARCEL MILLER

President Alstom Belgium / Chairman
of the Board of Agoria Wallonia / Vice Chairman
of the Board of UWE (Walloon Business
Association) / Director of Technord / Member of
the Audit Committee

JEROEN CAMMERAAT

CEO and co-investor in i-Optics BV

REFERENCE TABLE

Ticker	Euronext: IBAB Reuters: IBA.BR Bloomberg: IBA.BB
Sector	Healthcare Equipment & Services
Market capitalization	EUR 684 819 128*
Year end	December 31
Next reporting date	August 27, 2015 Publication H1 2015 results

*As at March 31, 2015

ANALYST COVERAGE

KBC Securities	Jan De Kerpel Tel. : +32 2 429 84 67 Mail : jan.dekerpel@kbcsecurities.be
Petercam	Roderick Verhelst Tel. : +32 2 229 66 82 Mail : roderick.verhelst@petercam.be
Jefferies	Martin Bruninger Mail : m.bruninger@jefferies.com

INVESTOR RELATIONS

CFO of IBA	Jean-Marc Bothy Tel.: +32 10 47 58 90 Mail : investorrelations@iba-group.com
Media enquiries	Amber Bielecka, Matthew Neal, Ivar Milligan, Jessica Hodgson Tel.: +44 (0)20 3709 5700 Mail: IBA@consilium-comms.com
Rx Communications Group (US)	Melody Carey Tel.: +1 917 322 2571 Mail: mcarey@RxIR.com

IBA STOCK MARKET PRICES



SIGNIFICANT SHAREHOLDERS

MARCH 31, 2015

Belgian Anchorage SCRL*	21.65%
Institut des Radio éléments FUP	4.97%
SRIW	2.46%
IBA Invest	2.13%
Sopartec SA	1.20%
Université Catholique de Louvain (UCL)	1.49%

Belgian Anchorage is a company established and wholly owned by IBA Management and a number of IBA employees.